Chaffey Breeze : reported that Vetr Inc. Downgrades Cempra Inc (CEMP) to Strong Sell

Downgrades Cempra Inc (CEMP) to Strong Sell" was first published by Chaffey Breeze and is the property of of Chaffey Breeze. Cempra Company ProfileCempra, Inc is a clinical-stage pharmaceutical company. Vetr's target price indicates a potential downside of 15.31% from the stock's current price. Cempra Inc (NASDAQ:CEMP) was downgraded by equities researchers at Vetr from a "buy" rating to a "strong sell" rating in a research note issued to investors on Monday. Following the completion of the sale, the director now directly owns 95 shares of the company's stock, valued at $323.95.

Cempra Inc (CEMP) Raised to Buy at Roth Capital

The brokerage presently has a $2.50 price target on the stock, down from their prior price target of $8.00. Needham & Company LLC downgraded shares of Cempra from a "buy" rating to a "hold" rating in a research report on Wednesday, November 23rd. Cempra Inc (NASDAQ:CEMP) was upgraded by investment analysts at Roth Capital from a "neutral" rating to a "buy" rating in a report released on Monday. Vetr downgraded shares of Cempra from a "buy" rating to a "strong sell" rating and set a $3.43 target price for the company. Roth Capital's target price indicates a potential downside of 38.27% from the stock's previous close.

Cempra Inc (CEMP) to Release Quarterly Earnings on Tuesday

Cempra Company ProfileCempra, Inc is a clinical-stage pharmaceutical company. Cempra Inc (NASDAQ:CEMP) will be issuing its quarterly earnings data before the market opens on Tuesday, February 28th. Raymond James Financial, Inc. reissued a "market perform" rating on shares of Cempra in a research note on Wednesday, November 2nd. An institutional investor recently bought a new position in Cempra stock. Also, Director Dov A. Md Goldstein sold 105,460 shares of the company's stock in a transaction on Friday, January 13th.



collected by :Lucy William
To follow all the new news about

VIRUSES and INFECTIONS